Juno Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015
ASSETS
Current assets:
Cash and cash equivalents
Marketable securities
Accounts receivable
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Long-term marketable securities
Goodwill
Intangible assets, net
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued liabilities and other current liabilities
Success payment liabilities
Build-to-suit lease obligation
Contingent consideration
Deferred revenue
Total current liabilities
Build-to-suit lease obligation, less current portion
Long-term debt, less current portion
Contingent consideration, less current portion
Deferred revenue, less current portion
Deferred tax liabilities
Other long-term liabilities
Tenant improvement allowance, deferred rent, and other long-term liabilities
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value, 495,000 shares authorized at December 31, 2017 and 2016; 114,313 and 103,403 shares issued and outstanding at December 31, 2017 and 2016, respectively
Additional paid-in-capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments